Cargando…
iNKT: A new avenue for CAR-based cancer immunotherapy
Chimeric antigen receptor (CAR) T cell is a T lymphocyte-based immunotherapy, which achieves great successes in treating blood malignancies and provides new hope to cue advanced cancer patients. Invariant natural killer T (iNKT) cells are a kind of special T lymphocytes characterized by expressing i...
Autores principales: | Liu, Yilin, Wang, Gang, Chai, Dafei, Dang, Yuanyuan, Zheng, Junnian, Li, Huizhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784340/ https://www.ncbi.nlm.nih.gov/pubmed/35063813 http://dx.doi.org/10.1016/j.tranon.2022.101342 |
Ejemplares similares
-
Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy
por: Aoki, Takahiro, et al.
Publicado: (2023) -
Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
por: McNerney, Kevin O., et al.
Publicado: (2020) -
22511 Glycolipid-loaded nanoparticles harness iNKT cells for tumor immunotherapy
por: Shute, Travis, et al.
Publicado: (2021) -
iNKT and MAIT Cell Alterations in Diabetes
por: Magalhaes, Isabelle, et al.
Publicado: (2015) -
The Role of Autophagy in iNKT Cell Development
por: Yang, Guan, et al.
Publicado: (2018)